Probiotics as a Therapeutic Approach in Colorectal Cancer.

CRC management Colorectal cancer complications prevention probiotics treatment

Journal

Current cancer drug targets
ISSN: 1873-5576
Titre abrégé: Curr Cancer Drug Targets
Pays: Netherlands
ID NLM: 101094211

Informations de publication

Date de publication:
2023
Historique:
received: 05 11 2022
revised: 05 02 2023
accepted: 09 02 2023
medline: 29 8 2023
pubmed: 19 4 2023
entrez: 18 4 2023
Statut: ppublish

Résumé

Colorectal cancer (CRC) is a growing concern worldwide. In recent decades, the incidence of CRC has increased, and this has been attributed to changes in lifestyle. The lack of physical activity, smoking habits, and a diet high in red meat and fat and low in fiber are important aspects of these deleterious changes in lifestyle. The increase in the incidence of CRC has impelled researchers to investigate methods for preventing and treating CRC with greater efficacy and fewer complications. Probiotics are an attractive and potentially promising therapeutic approach. They have been evaluated by a large number of preclinical and clinical studies in recent years, and it has been found that they can play a role in the prevention, treatment, and management of complications of CRC. This review provides a concise summary of the mechanisms of action of probiotics. Furthermore, it focuses on the results of clinical and preclinical studies that evaluated probiotics' effects on CRC management. It also discusses the effects of different strains of probiotics and their combination in CRC treatment.

Identifiants

pubmed: 37069719
pii: CCDT-EPUB-130892
doi: 10.2174/1568009623666230413081513
doi:

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

764-777

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Nafiseh Rahmani (N)

Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Ghazaleh Pourali (G)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Nayyerehalsadat Hosseini (N)

Department of Human Genetics, School of Medicine, Virginia Commonwealth University, Virginia, VA, USA.

Hamid Fiuji (H)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Mina Maftooh (M)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Seyed Mahdi Hassanian (SM)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Gordon A Ferns (GA)

Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, BN1 9PH, UK.

Majid Khazaei (M)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Amir Avan (A)

Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Brisbane, QLD, 4059, Australia.
Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4102, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH